Sorry, you need to enable JavaScript to visit this website.
Pfizer Oncology
Loading...

The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

CEACAM5-directed Antibody Drug Conjugate

Geo Regions

CEACAM5-directed Antibody Drug Conjugate

PF-08046050 | SGN-CEACAM5C is an investigational compound. Its safety and efficacy have not been established.

Share to an HCP

Overview + Rationale

  • A member of the CEACAM sub-group family of glycoproteins involved in cell adhesion.1
  • Highly expressed in several tumors of epithelial origin such as CRC, PDAC, GC, and NSCLC.2
  • Normally expressed during fetal development limited in adults.1,2
  • CEACAM5C is an investigational antibody-drug conjugate, comprising a monoclonal antibody directed to CEACAM5 and a novel TOP1 inhibitor linker-payload system, which enables preferential release of a potent topoisomerase 1 inhibitor within target cells.3

Mechanism of Action

Proposed Mechanism of Action of a CEACAM5-Directed, Next-Generation Antibody-Drug Conjugate with Novel Topoisomerase 1 Inhibitor Payload

Stage of Development

small icon representing Other Cancer types
Advanced Solid Tumors
Phase 1 Monotherapy
This information is current as of February 4th 2025.

CEACAM5, carcinoembryonic antigen cell adhesion molecule 5 

REFERENCES: 1. Thomas J. Genes Cancer. 2023: 12-29. 2. Decary S. Clin Cancer Res. 2020: 6589-99. 3. Baudat Y. Cancer Res. 2023: 4890. 4. Clinicaltrials.gov. Clinicaltrials.gov. https://clinicaltrials.gov/study/NCT06131840. Accessed January 16, 2025.